FGF-1 vs TB4-Frag

Binds all four FGFR subtypes (broadest binding of FGF family). Activates MAPK and PI3K downstream pathways. Promotes fibroblast proliferation, angiogenesis, and hair follicle cycling into anagen phase.

FGF-1 (fibroblast growth factor 1; acidic FGF; aFGF) is an endogenous 155-amino-acid heparin-binding growth factor and the prototypic member of the 22-member FGF family, expressed in diverse tissues where it stimulates cell proliferation, survival, and migration through tyrosine kinase receptor (FGFR1-4) signaling, with particularly important roles in angiogenesis, wound healing, and tissue repair. FGF-1 activates FGFR to initiate MAPK/ERK, PI3K/Akt, and PLCgamma signaling cascades driving endothelial cell sprouting and neovascularization; in ischemic tissues, FGF-1 is a potent inducer of therapeutic angiogenesis, stimulating new vessel formation to restore perfusion in peripheral arterial disease and critical limb ischemia. A Phase 2 randomized controlled trial of intramuscular gene-encoded FGF-1 delivery (NV1FGF, a non-viral plasmid vector) in critical limb ischemia demonstrated improved amputation-free survival in human subjects, providing clinical evidence for FGF-1 pathway activity; this gene therapy approach is distinct from direct recombinant FGF-1 protein administration, and no protein therapy form has completed Phase 3 trials. Recombinant FGF-1 protein has no FDA approval as a standalone therapeutic; the clinical evidence base references gene-encoded delivery rather than the protein itself, and research-grade FGF-1 is used primarily as a cell culture supplement and tissue engineering scaffold factor rather than as a therapeutically administered agent.

Active fragment of Thymosin Beta-4; promotes actin dynamics and cell migration; activates hair follicle stem cells; modulates inflammatory signaling

TB-4 Fragment (Thymosin Beta-4 17-23) is a short synthetic peptide derived from the thymosin beta-4 protein, investigated for wound healing, skin repair, and hair follicle regeneration. Thymosin beta-4 facilitates actin sequestration, keratinocyte migration, and stem cell recruitment to sites of tissue injury; the 17-23 fragment retains portions of these bioactive properties. Peer-reviewed studies demonstrate that thymosin beta-4 promotes hair follicle stem cell activation and dermal tissue regeneration in preclinical models, providing a mechanistic basis for skin-related applications. TB-4 Fragment is an investigational peptide with limited human clinical data and is not approved by the FDA for any therapeutic use. TB4-Frag vs full-length thymosin beta-4 TB-4 Fragment (residues 17–23 of thymosin beta-4, sequence: Leu-Lys-Lys-Thr-Glu-Thr-Gln) is a distinct, smaller molecule compared to full-length thymosin beta-4 (43 amino acids). The fragment retains the actin-binding motif that drives keratinocyte migration and stem cell recruitment — mechanisms central to the wound healing and hair follicle regeneration research attributed to TB4 — but lacks the full protein's Ac-SDKP-generating and anti-fibrotic properties. The lower molecular weight of the fragment (approximately 870 Da vs ~4,900 Da for full Tb4) is proposed to improve transdermal penetration for topical applications, making TB4-Frag relevant to cosmetic skin and scalp formulations where injectable administration is not used. In the research peptide market, TB4-Frag is positioned as a topical active for skin repair and hair density contexts; full-length thymosin beta-4 (sold as TB-500) is used for systemic/injectable recovery and tissue repair applications. The two should not be conflated — they have different sequences, molecular weights, and proposed application contexts despite sharing a mechanistic origin.